furosemide has been researched along with 19-hydroxy-4-androstene-3,17-dione in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (33.33) | 18.7374 |
1990's | 2 (66.67) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Mercado-Asis, LB; Miura, K; Miyazaki, S; Morita, H; Mune, T; Murayama, M; Yamakita, N; Yasuda, K | 1 |
Ohsawa, N; Sekihara, H | 1 |
Miura, K; Miyazaki, S; Morita, H; Mune, T; Yamakita, N; Yasuda, K | 1 |
1 trial(s) available for furosemide and 19-hydroxy-4-androstene-3,17-dione
Article | Year |
---|---|
Low plasma 19-hydroxyandrostenedione levels in patients with aldosterone-producing adenoma.
Topics: Adenoma; Adrenal Gland Neoplasms; Adult; Aged; Aldosterone; Androstenedione; Blood Pressure; Dexamethasone; Female; Furosemide; Humans; Hypertension; Male; Middle Aged; Radioimmunoassay | 1993 |
2 other study(ies) available for furosemide and 19-hydroxy-4-androstene-3,17-dione
Article | Year |
---|---|
Secretory regulation of 19-hydroxyandrostenedione in normal man.
Topics: Adolescent; Adult; Aldosterone; Androstenedione; Captopril; Cosyntropin; Dexamethasone; Female; Furosemide; Humans; Hydrocortisone; Male; Middle Aged; Pituitary-Adrenal System; Radioimmunoassay; Renin; Renin-Angiotensin System | 1992 |
19-hydroxyandrostenedione, a new amplifier of the action of aldosterone, in low renin essential hypertension.
Topics: Addison Disease; Adrenocorticotropic Hormone; Aldosterone; Androstenedione; Cushing Syndrome; Female; Furosemide; Humans; Hypertension; Male | 1982 |